Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection

Background In clinical trials, a pangenotype direct‐acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy and tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings in real‐world settings, focusing on patients with cirrhosis, history of DAA failure, or HCV genotype 3 who were treated with a 12‐week regimen in a large...